The clinical trials are over! Following in the path of the FDA and the European Committee for Medicinal Products for Human Use, Health Canada has approved Gilenya (also known as Fingolimod) - the first oral treatment (read: disease modifying drug) for Relapsing Remitting MS!
And like Tysabri (the once-per-month IV infusion), Gilenya will not be a "first" treatment, as the risks are higher* when compared to beta-interferons or glatiramer acetate. High risk, potentially better reward...so try the injections first. Gilenya is approved for people who have tried more than one DMD, and are either unresponsive or intolerant to these treatments.
*during the trials, there were cases of skin cancer and inflammation of the brain